ISLET Act
HR 4304, the ISLET Act, amends federal regulations to clarify that human cadaveric islets (islet cells from deceased donors) are not classified as drugs, biological products, or human cells/tissues under existing law. This removes regulatory barriers for islet transplantation programs treating endocrine conditions like diabetes. The bill requires the Health and Human Services Secretary to update relevant regulations within one year and report progress to Congress within six months. It directly affects transplant centers, researchers, and patients seeking islet-based therapies by streamlining their regulatory pathway.
Bill status
in committee
1 of 4 stages cleared
Introduction
Jun 2023
Committee Review
Floor Vote
President
Introduced Jun 22, 2023
Last action Jun 23, 2023
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
3
Key actions
0
Committee
2
Jun 23, 2023
Committee
Referred to the Subcommittee on Health.
lower
Jun 22, 2023
Committee
Referred to the House Committee on Energy and Commerce.
lower
Jun 22, 2023
Introduced
Introduced in House
lower
1 primary · 4 co-sponsors
Sponsors
Ask Maddy
·
AI policy assistant
Ask Maddy about HR 4304
Scope: US
Hi! I can help you understand HR 4304. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline